

Yu Zuo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/823779/publications.pdf>

Version: 2024-02-01

24
papers

3,552
citations

516561

16
h-index

610775

24
g-index

28
all docs

28
docs citations

28
times ranked

7204
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	1,193
2	Neutrophil extracellular traps in COVID-19. <i>JCI Insight</i> , 2020, 5, .	2.3	988
3	Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	491
4	Neutrophil extracellular traps and thrombosis in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 446-453.	1.0	201
5	Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 1580.	1.6	175
6	Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. <i>Journal of Leukocyte Biology</i> , 2021, 109, 67-72.	1.5	107
7	Autoantibodies stabilize neutrophil extracellular traps in COVID-19. <i>JCI Insight</i> , 2021, 6, .	2.3	53
8	Endothelial Cell-Activating Antibodies in COVID-19. <i>Arthritis and Rheumatology</i> , 2022, 74, 1132-1138.	2.9	47
9	New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm. <i>JCI Insight</i> , 2020, 5, .	2.3	36
10	SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. <i>Viruses</i> , 2021, 13, 2209.	1.5	36
11	The interplay between neutrophils, complement, and microthrombi in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101661.	1.4	35
12	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2020, 7, 3-12.	1.3	26
13	Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. <i>JCI Insight</i> , 2021, 6, .	2.3	23
14	Antiphospholipid syndrome: a clinical perspective. <i>Chinese Medical Journal</i> , 2020, 133, 929-940.	0.9	22
15	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). <i>Lupus</i> , 2021, 30, 2276-2285.	0.8	21
16	Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?. <i>Current Rheumatology Reports</i> , 2018, 20, 66.	2.1	16
17	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020, 32, 215-227.	2.0	8
18	Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series. <i>Pediatric Rheumatology</i> , 2022, 20, 17.	0.9	7

#	ARTICLE	IF	CITATIONS
19	A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. <i>Lupus</i> , 2017, 26, 606-615.	0.8	6
20	Identifying Additional Risk Factors for Thrombosis and Pregnancy Morbidities Among Antiphospholipid Antibodies Carriers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 980-985.	0.7	6
21	Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers. <i>Lupus</i> , 2021, 30, 828-832.	0.8	6
22	Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS. <i>Rheumatology</i> , 2022, 61, 4962-4974.	0.9	3
23	The role of cardiovascular disease risk assessed by ASCVD score in primary thrombosis prophylaxis strategy among antiphospholipid antibody carriers. <i>Lupus</i> , 2018, 27, 2177-2178.	0.8	2
24	Myopathy in a 61-year-old Hispanic man. <i>BMJ Case Reports</i> , 2019, 12, e228892.	0.2	1